News


December 20th, 2017

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

Vancouver, British Columbia – Dec 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system is pleased to report that they will be presenting clinical outcome data from Qu’s recently completed Phase 2 study in ulcerative colitis at […]

READ MORE >
November 28th, 2017

Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

Vancouver, British Columbia – November 28th, 2017 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the […]

READ MORE >
October 3rd, 2017

Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers

Vancouver, British Columbia – October 3rd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has identified specific ulcerative colitis (UC) genetic markers that may predict response to QBECO SSI therapy and important immunological biomarkers that may be […]

READ MORE >
August 14th, 2017

Positive feedback from FDA reviewers in response to Pre-IND meeting package

Vancouver, British Columbia – August 14th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports positive and informative feedback from the US Food and Drug Administration (FDA) in response to Qu’s first Pre-IND meeting package submission. The […]

READ MORE >
August 2nd, 2017

Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement

Vancouver, British Columbia – August 2nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high clinical and endoscopic response rates in its recently completed Phase 2, open-label, dose ranging trial in study participants with moderate to […]

READ MORE >
August 2nd, 2017

Qu Biologics invited to present at US National Cancer Institute (NCI) Conference

Vancouver, British Columbia – July 12th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, is pleased to announce that CEO Dr. Hal Gunn, was invited to present at the US National Cancer Institute’s Microbial-Based Cancer Therapy Conference […]

READ MORE >
July 7th, 2017

More Qu Biologics international research presentations

Dr Hal Gunn, CEO of Qu Biologics, has been invited to present at the US National Cancer Institute (NCI) Conference on Microbial-Based Cancer Therapy. His topic for presentation is “Site-Specific Immunomodulators: Harnessing the Intrinsic Immune Capacity to Prevent and Fight Malignancy”.  Initiated by the NCI Office of Cancer Complementary and Alternative Medicine, the aim of this […]

READ MORE >
May 24th, 2017

Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)

Vancouver, British Columbia – May 23, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the body’s innate immune system, announces the peer-reviewed publication of proof of principle data in chronic obstructive pulmonary disease (COPD) in the journal, Respiratory Research.  The study demonstrates success with Qu Biologics’ QBKPN SSI in reducing […]

READ MORE >
May 4th, 2017

Qu Biologics invited to present Research Data at International Scientific Meetings

Vancouver, British Columbia – May 3rd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, is pleased to announce that Qu Biologics’ scientists will be presenting their research findings at several upcoming international scientific meetings. The presented data […]

READ MORE >
April 19th, 2017

High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease

Vancouver, British Columbia – April 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high response and remission rates in anti-TNFα naïve patients in its recently completed randomized, placebo controlled trial in moderate to severe Crohn’s […]

READ MORE >

Past events:


Past events: